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j ourna l homepage: www.eb iomed ic ine.comEditorialCRISPR–Cas9 Based Therapeutics: Not So FastGeneticists from Guangzhou, China recently shocked the scientiﬁc
community by publishing what appears to be the ﬁrst attempt at using
CRISPR–Cas9 genomic-editing technology to modify disease-associated
DNAs from human embryos. The article appeared in the May 2015 issue
of Protein & Cell.
The experiments did not gowell. Although endogenous target genes
were cleaved as expected—cleavage occurred in only about half of the
embryos tested. Additionally, the researchers observed that the uptake
of the “repair” sequence was inefﬁcient, occurring in only a small
fraction of the embryos. More seriously, a high degree of off-target mu-
tations was observed. Given the dangers of heritable off-target muta-
tions in the germline, as well as the polarizing ethical considerations
that must be considered when modifying human genomes, this study
solidiﬁes concerns of many in the scientiﬁc community that we are a
long way off from using the CRISPR–Cas9 system as a tool for human
gene therapy. However, considering the potential speciﬁcity and inher-
ent ease of the system, it seems unlikely that exploration and discussion
of this tool as a means of treating human genetic disease will end any
time soon.
The system holds much promise. First identiﬁed in bacteria as a de-
fense mechanism against invading pathogens, CRISPR–Cas9 works by
using a small guide RNA sequence that corresponds precisely to the
DNA target of interest. When combined with the Cas9 nuclease, these
highly-speciﬁc guide RNA–Cas9 complexes bind directly to the gene of
interest and mediate the direct double-stranded cleavage of the target
DNA. It is then possible to inactivate the gene, or to replace a defective
gene with a healthy version. By modifying the enzymatic activity of
Cas9, it is also possible to turn the gene on (instead of cleaving it), or
to alter the gene's expression. One can envisage the limitless possibili-
ties that such highly-speciﬁc, targeted genetic manipulation holds for
biomedical research and medicine.
For example, scientists have employed CRISPR–Cas9 to effectively
“cure” cells latently infectedwithHIVby excising the integrated proviral
DNA from the host cell. Although these studies were performed ex vivo,
given the difﬁculties researchers have faced in identifying and eliminat-
ingHIV reservoirs from infected patients, this approachwould be awel-
come addition to our arsenal of HIV therapeutics. There have also been
proof-of-principle studies where other DNA viruses such as hepatitis B
and papillomavirus have been successfully targeted—and one can imag-
ine a future where clinicians may use CRISPR–Cas9 as an easy-to-
generate, nimble antimicrobial option against not only well-known,
but also against suddenly emerging, DNA-based viral and perhaps also
bacterial pathogens.http://dx.doi.org/10.1016/j.ebiom.2015.05.015
2352-3964/© 2015 Published by Elsevier B.V. This is an open access article under the CC BY-NCScientists have also used the system to treat genetically-based de-
fects in animal disease models. One recent study employing a mouse
model of hereditary tyrosinemia, for example, showed that injection
of CRISPR–Cas9 complexes speciﬁcally targeting the defective disease-
associated Fah gene resulted in successful expression of the wild-type
gene in the livers of targeted mice, but only in a small fraction of the
liver cells. However, the researchers were able to correct phenotypic
weight loss if they ﬁrst expanded these modiﬁed cells ex vivo before
transplanting them back into the mice. Some amendments to disease-
targeting approaches may therefore be necessary to see phenotypic ef-
fects at the whole animal level, depending on the mode of delivery, the
gene being targeted, and the disease under consideration.
Although RNAi has revolutionized our ability to efﬁciently and
cheaply “knock-down” a gene's function by targeting the cleavage of
its messenger RNA, CRISPR–Cas9 has taken gene targeting to a new
level by silencing the gene at the source. Hoping to overcome some of
the off-targeting and sometimes incomplete suppression issues inher-
ent with RNAi, researchers have turned to CRISPR–Cas9 not only for
therapeutic applications, but also as a basic tool for screening gene func-
tion at both the individual gene as well as at the genome-wide level.
Genome-wide screens have been performed using CRISPR to look for
speciﬁc genes mediating resistance to cancer drugs and certain patho-
gens, for example, as well as toward understanding which genes may
be involved in mediating speciﬁc disease outcomes such as lungmetas-
tasis. We are really only at the beginning of the era of using CRISPR as a
genetic screening tool.
Despite the promise and utility of the CRISPR–Cas9 system, great
challenges and worries remain regarding its application as a human
therapeutic tool. Given the degree of unexpected off-target germline
mutation rates observed in the Guangzhou human embryo study, safety
and ethical concerns are naturally at the top of our list of concerns.
When considering CRISPR–Cas9 as a therapeutic application, we must
proceed with caution and due diligence, taking into consideration all
ethical and scientiﬁc imperatives. In addition to improving speciﬁcity
and eliminating off-target effects, technical challenges also remain re-
garding in vivo delivery, as well as the potential for immunogenicity
of the complex.
“With great power, comes great responsibility.” Although the origin
of this quote is debatable, the message is not. We urge our readers to
walk—and not run—toward embracing this next generation of gene
therapy tools.
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